CA2512232A1 - Device for filtering blood in a vessel with helical elements - Google Patents
Device for filtering blood in a vessel with helical elements Download PDFInfo
- Publication number
- CA2512232A1 CA2512232A1 CA002512232A CA2512232A CA2512232A1 CA 2512232 A1 CA2512232 A1 CA 2512232A1 CA 002512232 A CA002512232 A CA 002512232A CA 2512232 A CA2512232 A CA 2512232A CA 2512232 A1 CA2512232 A1 CA 2512232A1
- Authority
- CA
- Canada
- Prior art keywords
- helix
- drug
- size
- opposite end
- vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title description 10
- 239000008280 blood Substances 0.000 title description 10
- 238000001914 filtration Methods 0.000 title description 6
- 239000011148 porous material Substances 0.000 claims abstract description 61
- 239000000463 material Substances 0.000 claims abstract description 48
- 208000005189 Embolism Diseases 0.000 claims abstract description 16
- 229910001000 nickel titanium Inorganic materials 0.000 claims abstract description 10
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 57
- 230000007246 mechanism Effects 0.000 claims description 23
- 238000004873 anchoring Methods 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000012781 shape memory material Substances 0.000 claims description 12
- 239000000824 cytostatic agent Substances 0.000 claims description 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960002930 sirolimus Drugs 0.000 claims description 10
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- 230000001085 cytostatic effect Effects 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 9
- 229910001092 metal group alloy Inorganic materials 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 description 30
- 235000019994 cava Nutrition 0.000 description 13
- 208000010378 Pulmonary Embolism Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- -1 germicides Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000005465 channeling Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 229960003418 phenoxybenzamine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- LSBUIZREQYVRSY-CYJZLJNKSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 LSBUIZREQYVRSY-CYJZLJNKSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- VWXFUOAKGNJSBI-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide Chemical compound C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl VWXFUOAKGNJSBI-UHFFFAOYSA-N 0.000 description 1
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- UVBMFLQXZPETMM-UHFFFAOYSA-N 3-(2-aminophenyl)-3-ethylpiperidine-2,6-dione Chemical compound C=1C=CC=C(N)C=1C1(CC)CCC(=O)NC1=O UVBMFLQXZPETMM-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- VJNXVAVKCZJOFQ-UHFFFAOYSA-N Phenmetrazine hydrochloride Chemical compound Cl.CC1NCCOC1C1=CC=CC=C1 VJNXVAVKCZJOFQ-UHFFFAOYSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229940024544 aluminum aspirin Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 description 1
- 229960002138 anisindione Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 229960003228 benzphetamine hydrochloride Drugs 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- ICZOIXFFVKYXOM-YCLOEFEOSA-M cefamandole nafate Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)C=3C=CC=CC=3)[C@H]2SC1 ICZOIXFFVKYXOM-YCLOEFEOSA-M 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940084959 cephalexin hydrochloride Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- SOELXOBIIIBLRJ-UHFFFAOYSA-M choline theophyllinate Chemical compound C[N+](C)(C)CCO.CN1C(=O)N(C)C([O-])=C2N=CN=C21 SOELXOBIIIBLRJ-UHFFFAOYSA-M 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960000267 diphenadione Drugs 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229950007285 etintidine Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940065346 hydroxyprogesterone acetate Drugs 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229940005535 hypnotics and sedatives Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
- 229960002931 methacholine chloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229950008080 mioflazine Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
- 229950011191 norgesterone Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 229950005116 phenaglycodol Drugs 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- 229960002315 phenmetrazine hydrochloride Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000002373 plant growth inhibitor Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
- 229960003253 procainamide hydrochloride Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002153 prochlorperazine maleate Drugs 0.000 description 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- JFNWFXVFBDDWCX-UHFFFAOYSA-N sulfisoxazole acetyl Chemical compound C=1C=C(N)C=CC=1S(=O)(=O)N(C(=O)C)C=1ON=C(C)C=1C JFNWFXVFBDDWCX-UHFFFAOYSA-N 0.000 description 1
- 229950006904 sulfisoxazole acetyl Drugs 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- RVBRTNPNFYFDMZ-SPIKMXEPSA-N thiethylperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 RVBRTNPNFYFDMZ-SPIKMXEPSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XJGONMZLEDGBRM-UHFFFAOYSA-M tridihexethyl chloride Chemical compound [Cl-].C=1C=CC=CC=1C(O)(CC[N+](CC)(CC)CC)C1CCCCC1 XJGONMZLEDGBRM-UHFFFAOYSA-M 0.000 description 1
- 229960001205 tridihexethyl chloride Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/0103—With centering means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2002/018—Filters implantable into blood vessels made from tubes or sheets of material, e.g. by etching or laser-cutting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/068—Modifying the blood flow model, e.g. by diffuser or deflector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0091—Three-dimensional shapes helically-coiled or spirally-coiled, i.e. having a 2-D spiral cross-section
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0095—Saddle-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0266—Shape memory materials
Abstract
A device for capturing an embolus within a vessel of a patient's body has at least one helix made of a mesh material. The at least one helix has a plurality of turns helically arranged around a longitudinal axis. The mesh material has a plurality of pores therein and the pores have a size >= 120 µm. The at least one helix includes a plurality of panels wherein the panels are movable from a collapsed state to an expanded state when placed within a vessel. The mesh material is made of a self expanding material such as nickel titanium in one embodiment. In another embodiment, the device has a double helix arrangement.
Description
DEVICE FOR FILTERING BLOOD IN A VESSEL WITH HELICAL
ELEMENTS
FIELD AND BACKGROUND OF THE INVENTION
In the human cardiovascular and circulatory system, the consistency of blood remains liquid enough for the blood cells and other molecules to travel smoothly through the arteries and veins. Sometimes, however, clots will form in a process called coagulation. When clots or other blood-borne clumps of tissue migrate through the circulatory system, they are called emboli; a single migrating clot is 1 o called an embolus or an embolism.
A pulmonary embolism is a clot that travels through the venous system and eventually lodges in the pulmonary artery, which carries blood from the heart to the lungs. This can obstruct the blood supply to the lungs, which is potentially fatal and 15 should be treated as an emergency.
Many pulmonary emboli result from a condition called deep vein thrombosis (DVT). DVT is the formation of a blood clot in the veins embedded deep in the muscles, usually in the lower Ieg and sometimes in the pelvis or groin.
Versa cava filters, tiny nets, help prevent emboli from traveling through the heart and into the lungs. Most commonly, versa cava filters are inserted into the inferior versa cava, a large vein that carries blood from the lower extremities.
Versa cava filters are normally metallic, umbrella-shaped devices that catch blood clots to prevent them from traveling to the lungs and causing a pulmonary embolism. Versa cava filters usually are used when drug therapy, such as treatment with blood-thinners, has failed or is considered inadequate, or when drug therapy would cause other dangerous medical conditions.
The procedure is safe and effectively reduces the risk of pulmonary embolism in most people when performed by a practitioner who is skilled in filter insertion and when complemented by drug therapies.
People most likely to receive a versa cava filter are those at risk for pulinonary embolism and those for whom drug or other therapy is considered inadequate. Versa cava filters are also inserted to protect trauma patients from pulmonary embolism associated with their injuries.
1 o The procedure for placing a versa cava filter in a patient usually requires that the physician administer a local anesthetic at the insertion site, either the arm, neck, or groin, and makes an incision. Patients may also receive a muscle relaxant for additional comfort. Alternatively, the procedure may be performed while the patient is under general anesthesia.
The physician then inserts the collapsed filter into the incision via a catheter (a long, thin, flexible tube) and advances the filter to the versa cava. The physician then deploys the filter in the vein at the target location, removes the insertion device, and closes the incision. The procedure generally takes from 10 to 40 minutes.
ELEMENTS
FIELD AND BACKGROUND OF THE INVENTION
In the human cardiovascular and circulatory system, the consistency of blood remains liquid enough for the blood cells and other molecules to travel smoothly through the arteries and veins. Sometimes, however, clots will form in a process called coagulation. When clots or other blood-borne clumps of tissue migrate through the circulatory system, they are called emboli; a single migrating clot is 1 o called an embolus or an embolism.
A pulmonary embolism is a clot that travels through the venous system and eventually lodges in the pulmonary artery, which carries blood from the heart to the lungs. This can obstruct the blood supply to the lungs, which is potentially fatal and 15 should be treated as an emergency.
Many pulmonary emboli result from a condition called deep vein thrombosis (DVT). DVT is the formation of a blood clot in the veins embedded deep in the muscles, usually in the lower Ieg and sometimes in the pelvis or groin.
Versa cava filters, tiny nets, help prevent emboli from traveling through the heart and into the lungs. Most commonly, versa cava filters are inserted into the inferior versa cava, a large vein that carries blood from the lower extremities.
Versa cava filters are normally metallic, umbrella-shaped devices that catch blood clots to prevent them from traveling to the lungs and causing a pulmonary embolism. Versa cava filters usually are used when drug therapy, such as treatment with blood-thinners, has failed or is considered inadequate, or when drug therapy would cause other dangerous medical conditions.
The procedure is safe and effectively reduces the risk of pulmonary embolism in most people when performed by a practitioner who is skilled in filter insertion and when complemented by drug therapies.
People most likely to receive a versa cava filter are those at risk for pulinonary embolism and those for whom drug or other therapy is considered inadequate. Versa cava filters are also inserted to protect trauma patients from pulmonary embolism associated with their injuries.
1 o The procedure for placing a versa cava filter in a patient usually requires that the physician administer a local anesthetic at the insertion site, either the arm, neck, or groin, and makes an incision. Patients may also receive a muscle relaxant for additional comfort. Alternatively, the procedure may be performed while the patient is under general anesthesia.
The physician then inserts the collapsed filter into the incision via a catheter (a long, thin, flexible tube) and advances the filter to the versa cava. The physician then deploys the filter in the vein at the target location, removes the insertion device, and closes the incision. The procedure generally takes from 10 to 40 minutes.
2 o Antibiotics are prescribed as necessary to minimize the risk of infection.
Patients are likely to remain in the hospital until the supervising physician confirms that the filter is properly fixed in the versa cava and that there are no complications from the procedure. The presence of a versa cava filter does not affect daily routines or the use of other medications. Some patients may remain on anticoagulant drug therapy to reduce the risk of post-insertion clot formation, or risk enlarging a pre-existing clot.
However, there are known complications that may arise in any vena cava filter placement even though known vena cava filters are about 98 percent successful in preventing symptomatic pulmonary embolism. These known filter devices and their placement procedures can be associated with surgical and anesthesia complications to include: bleeding at the insertion site; anesthesia-associated complications such as an allergic reaction or breathing problems; stroke;
pulmonary embolism; and clots. And, as is well known in the field, these complications are not only serious to the patient's health, but they can also be fatal.
z o Thrombosis of the inferior vena cava (IVC) filter after filter placement is frequently reported and may occur with all types of filter presently used in the field.
The occurrence of thrombosis can be delayed from hours to several months after the filter placement, but seems more frequent during the first 3 months. Continued anticoagulation therapy has not been shown to prevent IVC thrombosis.
15 Studies have also shown adverse flow dynamics, such as increased pressure gradients, in the filters with high clot-trapping capacity. Accordingly a device that has a high clot capture efficiency while minimizing the potential for increased pressure gradient is desirable.
Accordingly, what is needed is a device and method that can further reduce 2 o these serious and fatal complications in a more reliable and predictable manner. To date, there have been no known filter devices that are designed in such a manner that can eliminate these complications on a consistent basis, particularly providing for the elimination of complications that may be attributed to pulmonary embolism and blood clots.
The present invention is a novel filter device and method for filtering blood in a vessel that is more highly effective in capturing clots and preventing pulmonary embolism over the known prior art devices and techniques.
SUMMARY OF THE INVENTION
The present invention is a novel filter device and novel method for filtering fluid or blood in a vessel or organ that is more highly effective in capturing clots, emboli, particulate matter and particles and preventing pulmonary embolism over the known prior art devices and techniques The device will also avoid plugging up and restricting blood flow.
The present invention is directed to various embodiments of devices and 1 o methods for trapping or capturing emboli in a vessel of patient's body or organ.
In one embodiment, the present invention is a device for capturing an embolus within a vessel of a patient's body, the device comprising:
at least one helix made of a mesh material, the at least one helix i 5 having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size > 120 ~.m.
2 o In another embodiment, the present invention is a device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the 25 expanded state, the mesh panels having a plurality of pores therein, the pores having a size >_ 120 Nxn.
In another embodiment, the present invention is a device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size > 120 dun.
Another embodiment for the present invention is directed to a method for capturing an embolus within a vessel of a patient's body, the method comprising the 1 o steps of providing a device comprising at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the z5 pores having a size > 120 pm; and placing the device within the vessel of the patient's body.
The method according to the present invention further includes the step of 2 o placing the device within the vessel of the patient's body by moving the device from a collapsed state to an expanded state when placed within a vessel. Other steps include anchoring the device to an inner wall of the vessel, for instance, through using a plurality of barbs.
25 Another embodiment for the present invention is directed toward a method for capturing an embolus within a vessel of a patient's body, the method comprising the steps of:
providing a device comprising at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size > 120 pm, the pores varying in size from a larger size at one end of the at least one helix to a smaller size at an opposite end of the at least one helix; and placing the device within the vessel of the patient's body.
Another method of the present invention is a method for trapping an embolus 1 o within a vessel of a patient's body, the method comprising the steps of providing a device comprising a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the expanded state, the mesh panels having a 1 s plurality of pores therein, the pores having a size > 120 lun; and placing the device within the vessel of the patient's body.
The method further includes the step of placing the device within the vessel of the patient's body by moving the mesh panels of the device from a collapsed state 2 o to an expanded state when placed within a vessel and anchoring the device to an inner wall of the vessel by using an anchoring mechanism or plurality of anchoring mechanisms such as a plurality of barbs.
Another method for the present invention is a method for trapping an 2s embolus within a vessel of a patient's body, the method comprising the steps of:
providing a device comprising a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size 120 pm; and placing the device within the vessel of the patient's body.
In all embodiments of the present invention, pore sizes can vary. For instance all pore sizes can be a size >_ 120 ~m.Moreover, in all embodiments of the present invention, the pore sizes of the device can vary from one end of the device to an opposite end of the device.
1 o For example, the pore size can vary from a larger size pore at one end of the device to a smaller size pore at an opposite end of the device wherein the pore size decreases throughout the entire length of the device, i.e. pore size decreases from the one end to the opposite end of the device such as found with depth type filter devices. The at least 15 one helix having a plurality of turns helically arranged around a longitudinal axis can vary in pitch. This pitch may decrease to zero, to the point where the helix ends by making a full revolution and contacts itself. Additionally, in all embodiments of the present invention, the pore size can be a uniform size throughout the device, 2 o i.e. from one end of the device to the opposite end of the device.
BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with particularity in the appended claims. The invention itself, however, both as to organization and methods of operation, together with further objects and advantages thereof, may be understood by reference to the following description, taken in conjunction with the accompanying drawings in which:
Fig. lA is a schematic illustration of a vessel in cross-section having a helical filter device for capturing emboli in accordance with the present invention;
Fig. I B is an enlarged illustration of a portion of the vessel and filter device of Fig. 1 capturing emboli therein in accordance with the present invention;
s o Fig. 2A is a schematic illustration of another embodiment of the filter device of Figs. 1 A and 1 B in accordance with the present invention;
Fig. 2B is a schematic illustration of the filter device of Fig. 2A haviag a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Fig. 3A is a schematic illustration of another embodiment of the filter device of Figs, lA and 1B having varying pore sizes extending from one end of the device to an opposite end thereof and also including an optional spine in accordance with z 0 the present invention;
Fig. 3B is a schematic illustration of the filter device of Fig. 3A having a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Fig. 4A is a schematic illustration of another embodiment of the filter device of Figs. lA and 1B having a double helix design in accordance with the present invention;
s Fig. 4B is a schematic illustration of the filter device of Fig. 4A having a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Figs. SA, SB and SC are schematic illustrations of a manufacturing method and method for expanding the filter device of Figs lA and 1B in accordance with the present invention; and 1 o Fig. 6 is a schematic illustration of the filter device and device for delivering the f lter device in accordance with the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is a filter device, generally designated 50, having a helical design that is either surface type filter (Figs lA, 1B, 2A, 2B, 4A and 4B) or depth type filter (Figs 3A and 3B) that may be employed in any generally cylindrical pathway such as a vessel IO (Figs. lA and 1B) such as a vein or artery, for example the versa cava, or a duct or an organ of the human body. The filter device 50 and method for using the device 50 is particularly useful for filtering a versa cava and more particularly useful for treatment of vascular disease such as DVT
although the z o device 50 and method of using same is not in any way limited to this particular anatomy or disease state.
The filter device 50 has a helix 55 (as either a single helix or double helix as better described later on below) that is particularly useful for trapping and capturing clots, emboli, particulate matter, particles and thrombus that are migrating or s 5 circulating throughout the circulatory system of the patient or are in danger of breaking apart from attached tissue or structure within the body and migrating or circulating throughout the circulatory system of the patient. As defined herein, the term "clot", "clots", "embolus", "embolism", "emboli", "particulate", "particulate matter", "matter", "particles", "filtrate"; "thrombus", and "thrombi" have the same 2 o meaning for purposes of this disclosure and are used interchangeably throughout and are generally designated as reference numeral 20.
The helix 55 of filter device 50 is made of a mesh material 52 having a plurality of pores 53 throughout the mesh 52. For example, the mesh 52 consists of a 2 s plurality of interlocking strands or fibers or an array of pores 53 made and arranged in the material 52 itself such as through cutting, etching, stamping or the like.
Details for the pores 53 are addressed below.
to The material 52 is any form of material. In one embodiment, the material 52 is a self expanding material such as shape-memory material which can be a metal alloy such as nickel titanium alloy (nitinol). In another embodiment, the material 52 is a stainless steel alloy.. Alternatively, the mesh material 52 is a polymer material. The polymer can be biodegradable and/or bioabsorbable. As used herein, the term "biodegradable" is defined as the breaking down or the susceptibility of a material or component to break down or be broken into products, byproducts, components or subcomponents over time such as days, weeks, months or years. As used herein, the term "bioabsorbable" is defined as the biologic elimination of any of the products of 1 o degradation by metabolism and/or excretion.
The expanded shape of the filter SO comprises at least one helix 55, for example a single helix (Figs lA, 1B, 2A, 2B, 3A and 3B) or a double helix (Figs. 4A
and 4B). The single helix 55 and double helix 55 respectively in some embodiments 1s of the invention comprise a plurality of pleats or panels 60 helically arranged around a longitudinal axis of the device 50. The panels 60 are helically arranged around the longitudinal axis in a plurality of helical turns 65. The helical turns 65 define an inner diameter (ID) and an outer diameter (OD) respectively. Alternatively, the helix 55 of the device 50 is constructed of a single piece of mesh material 52 or discrete 2 o sections of mesh 52 fused or connected to each other forming the single helix or double helix (Figs 4A and 4B) of the filter device 50. The helical turns 65 of filter device have uniform pitch, or alternatively have a variable pitch depending on the channeling effect desired by the end user.
25 It is preferable that the mesh 52 of each turn 65 is sloped, slanted, inclined or curved away from ID of helix 55 to OD of helix 55 such as depicted in the Figs., or alternatively, the helix 55 may have no incline or inclined toward the longitudinal axis. Since the mesh 52 is slanted or curved outwardly from ID to OD for each turn 65 of helix 55, fluid medium is forced and channeled toward the outer circumferential periphery of the helix 55. The panels 60 design for the helix 55 in the embodiments depicted in Figs. 1A and 1B facilitate this outward inclined feature and outward fluid channeling effect.
The helix 55 has a plurality of turns 65 helically arranged around a longitudinal axis that can vary in pitch. This pitch may decrease to zero, to the point where the helix 55 ends or terminates by making a full revolution and contacts itself.
to In some embodiments according to the present invention, the helix 55 includes a spine 57 as best illustrated in Figs 3A and 3B. The spine 57 serves as a central longitudinal shaft or axis for the helical turns 65 of the helix S5.
The spine 57 is optional for the helix 55 since the helix 55 can be constructed without this feature.
15 The filter device 50 is expandable from a compressed, closed, pre-deployed or collapsed state to an open, deployed or expanded state such as partially depicted in Figs SB and SC. For those embodiments having a plurality of panels 60 such as depicted in Figs. lA and 1B, the panels 60 of mesh 52 circumferentially expand upon deployment of the device 50 as best shown by direction arrows in Fig. 5B.
The 2 o filter device 50 is introduced into a lumen 15 of the vessel 10 in the compressed, closed, pre-deployed or collapsed state and the device SO is deployed in the lumen 15 of the vessel 10 by movable expansion of the helix 55 to the open, deployed or expanded state. When moved to the open, deployed or expanded state, the ID of the helix 55 roughly aligns along the longitudinal axis of the vessel 10 and the OD of 25 the helix 55 is adjacent inner wall 12 of the vessel 10.
Additionally, when moved to the open, deployed or expanded state, the helix 55 embeds itself in the wall I2 of the vessel 10 such as shown in Figs lA and 1B. As best illustrated in Figs. 2B, 3B, and 4B, anchoring mechanisms 68, such as a plurality of barbs 68, are used to secure the helix 55 in tissue such as the wall 12 of vessel 10.
The size for each pore 53 is > 120mm. Additionally, in all embodiments of the present invention, the pore size can be a uniform size throughout the entire length of the device 50, i.e. from one end of the device SO to the opposite end of the device 50.
1 o The filter device SO according to the present invention (all embodiments) provides the ability to expose a greater surface area of the filter device 50 due to the unique helix 55 feature. Based on its helical design, the filter device 50 permits a smaller pore structure 53 (over the known filters and filtering methods) because the possibility of stopping venous flow is eliminated. Accordingly, smaller sized clots 15 20, for instance clots 20 having a size >_ 120 p.tn, can be targeted and captured, thereby reducing risk to the patient, i.e, the risk of these smaller size clots 20 causing harm.
Moreover, in all embodiments of the present invention, the pore sizes of the 2 o filter device 50 can vary from one end of the device 50 to an opposite end of the device 50. For example, as best illustrated in Figs 3A and 3B, the pore size can vary from a larger size pore at one end of the device (for example a Smm pore size) to a smaller size pore 53 at an opposite end of the device 50 (for example a 120 wn pore size) such that the pore size decreases throughout the entire length of the device 50, 25 i.e. pore size decreases from the one end to the opposite end of the device 50 thereby increasing the useful life of the device 50 such as found with depth type filter devices. The larger clots 20 are captured at the beginning of the helix 55 of filter device 50 reserving the smaller pore structure portion at opposite or far end of the helix 55 of filter device 50 to remove the smaller clots 20.
The structure of the helix 55 is an expanded mesh 52 that creates the surface filter effect. Any particulate or clot 20 that approaches the filter device 50 according to the present invention encounters what appears to be a solid cylindrical impediment in the lumen 15 of vessel 10 (since OD of helix 55 circumferentially is expanded to and circumferentially conforms to inner wall 12 of vessel 10 as best shown in Figs lA and 1B). However the helical twist of helix 55 allows lower 1 o viscosity fluid medium (such as blood) to flow through pores 53 and around the mesh 52. Any particulate or clot 20 present in this fluid flow will impinge the mesh 52 of the helix 55 and either be trapped there, or be forced out toward the outer periphery of the helix 55 by a helical centrifugal flow effect. The helical structure of the filter device 50 according the present invention also induces outward force by z 5 the outward curvature or inclination of the mesh 52 where the particulate or clot 20 will be trapped. The fluid (blood) is free to move around and passed the clot 20, even if the filter structure is fully covered by particulate or clots 20.
There are several advantages to the helical filter design of the filter device 2 o according to the present invention, for example, the ability of the helix 55 of filter device 50 to filter large amounts of filtrate (clots 20) and completely avoid clogging or plugging the lumen 15 of vessel 10, i.e. vena cava 10 in this example. This is especially important since prior art filters increase the resistance in the lumen 15 of vessel 10 as they are eventually clogged or plugged by particulate matter (clots 20), 25 eventually restricting the flow within vessel 10 thereby cutting off or occluding fluid flow altogether.
The helical filter design of filter device 50 of the present invention captures the filtrate 20 by inertial impaction, or diverts it to the outside edges or periphery of the helix 55 thereby trapping it, while allowing the fluid medium (liquid or gas) to pass around the new obstruction created by the captured filtrate 20.
Other advantages of the filter device 50 of the present invention include the ability to generate a filter having different pore sizes from beginning to end as depicted in Figs. 3A and 3B, mimicking a depth type filter, thereby increasing the filter life. This variable pore size (along the length of the device 50) feature ensures 1 o that larger clots 20 will be captured at the beginning of the filter where the size of pores 53 are larger, reserving the smaller pore structure portion of the filter to remove the smaller clots 20.
Other advantages for the filter device 50 of the present invention relate to its 15 delivery, deliverability and manufacturability. For example, as depicted in Fig. SA, for those embodiments of the present invention made of shape memory material, such as nickel titanium as one example, the shape memory alloy is used as the structure of the filter 50 itself and will also serve as the delivery mechanism for the filter 50 as better described below.
As shown in Fig. SA, the filter device 50 can be laser cut in the general shape of a ribbon out of a tube 40 of shape memory material (nickel titanium in this example). The final cut shape taken from shape memory tube 40 is generally akin to a ribbon as best shown in Fig. 6. The cut device 50 (ribbon-like at this point) is 2 s loaded onto a shaft 82 of a catheter 80 which is akin to taking a ribbon and wrapping it around a pencil. The device 50 is loaded onto shaft 82 by advancing the shaft 82 as cut device 50 is circumferentially wrapped around shaft 82 so that there is no overlap of the device 50 on itself, thereby following a helical pattern. An optional cover 85 is used for the catheter 80 to-keep the wrapped and loaded device 50 compressed in its compressed, closed, pre-deployed or collapsed state.
One geometry, merely used as an example, is depicted in Figs. SA, SB and SC, where the initial shape of device 50 appears to be cut out of a ribbon (Fig. SA), but when expanded, one side/edge expands more than the other generating a circular path (Figs. SB and SC). When the circular path is given an axial component, the helical filter shape (helix 55) of filter device 50 is generated.
1 p Accordingly, as shown in Fig. 6, the filter device 50 according to the present invention provides for an extremely compact delivery method thereby providing flexibility in the delivery method. The helical shape (helix 55, i.e. single helix or double helix design) inherently conforms to the shaft 82 of the catheter 80 and is able to achieve a tight bend radius as shown. Thus, the filter device 50 is self s 5 centering and can easily adapt and function in a tightly constricted and bent environment.
Furthermore, variations for the filter device 50 are also contemplated herein according to the present invention. For example, as mentioned above, the helical 2 o turns 65 of the filter device 50 can have a variable pitch. Additionally, one end of the filter device 50 can coil in on itself, thereby providing an absolute type filter and eliminate any perception that a clot 20 may travel passed the filter 50.
Moreover, the filter device 50 is optionally coated with a drug such as a 25 cytotoxic drug or cytostatic drug in order to make the filter device 50 a drug eluting device for treatment of disease that responds to cytotoxic drugs (for example paclitaxel) or cytostatic drugs (for example one of the rapamycins) respectively. As used herein, the term "drug" or "drugs" are used interchangeably herein and define an agent, drug, compound, composition of matter or mixture thereof which provides some therapeutic, often beneficial, effect such as being cytotoxic or cytostatic as two examples.
This includes pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, antioxidants, plant growth promoters, plant growth inhibitors, preservatives, antipreservatives, disinfectants, sterilization agents, catalysts, chemical reactants, fermentation agents, foods, food supplements, nutrients, cosmetics, drugs, vitamins, sex sterilants, fertility inhibitors, fertility 1 o promoters, microorganism attenuators and other agents that benefit the environment of use. As used herein, the terms fizrther include any physiologically or pharmacologically active substance that produces a localized or systemic effect or effects in animals, including warm blooded mammals, humans and primates;
avians;
domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish;
reptiles; zoo and wild animals; and the like. The active drug that can be delivered includes inorganic and organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, 2 o synoptic sites, neuroeffector functional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants, antiparkinson agents, analgesics, anti-inflammatories, local anesthetics, muscle contractants, blood pressure medications and cholesterol lowering agents including statins, m antimicrobials, antimalarials, hormonal agents including contraceptives, sympathomimetics, polypeptides and proteins capable of eliciting physiological effects, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics, hypoglycemics, nutritional agents and supplements, grourth supplements, fats, ophthalmics, antienteritis agents, electrolytes and diagnostic agents.
Examples of the therapeutic agents or drugs useful in this invention include prochiorperazine edisylate, ferrous sulfate, aminocaproic acid, mecaxylamine 2 o hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride, isoproteronol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate 15 hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperazine maleate, anisindione, diphenadione, erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chlorpropamide, tolazamide, chlormadinone acetate, phenaglycodol, allopur-inol, aluminum aspirin, 2o methotrexate, acetyl sulfisoxazole, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-.beta.-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17-.beta.-hydroxyprogesterone acetate, nor-progesterone, norgestrel, norethindrone, norethisterone, norethiederone, 25 progesterone, norgesterone, norethynodrel, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, is ibuprofen, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, phenoxybenzamine, diltiazem, mili-inone, captropril, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenbufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuninal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinopril, enalapril, captopril, ramipril, enalaprilat, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptylin, and imipramine. Further examples are proteins and peptides which include, but are not s o limited to, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatropin, oxytocin, vasopressin, prolactin, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, 1 s interferons, interleukins, growth hormones such as human growth hormone;
bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors, and human pancreas hormone releasing factor.
2 o Moreover, drugs or pharmaceutical agents useful for the filter device 50 include: antiproliferative/antimitotic agents including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide, teniposide), antibiotics (dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin), anthracyclines, 25 mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (Ir asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents such as G(GP)IIbIIIa inhibitors and vitronectin receptor antagonists;
antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNL~ and analogs, streptozocin), s trazenes - dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine {cladribine}); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, 1 o aminoglutethimide; hormones (i.e, estrogen); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin);
antiinflammatory: such as adrenocortical steroids (cortisol, cortisone, i5 fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal agents (salicylic acid derivatives i.e. aspirin; para-aminophenol derivatives i.e. acetominophen; indole and indene acetic acids (indomethacin, sulindac, and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (ibuprofen and derivatives), 2 o anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives:
(cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); angiogenic agents: vascular endothelial growth factor 2 s (VEGF), fibroblast growth factor (FGF) platelet derived growth factor (PDGF), erythropoetin,; angiotensin receptor blocker; nitric oxide donors; anti-sense oligionucleotides and combinations thereof; cell cycle inhibitors, mTOR
inhibitors, growth factor signal transduction kinase inhibitors, chemical compound, biological molecule, nucleic acids such as DNA and RNA, amino acids, peptide, protein or combinations thereof.
It is to be understood that the use of the term "drug" or drugs" includes all s derivatives, analogs and salts thereof and in no way excludes the use of two or more such drugs.
The one or more drugs are coated on the filter device 50 itself or any desired portion of the device 50, for example, the outer circumferential edge of the helical 1 o turns 65. Moreover, the drug can be used with a polymer coating or the drug can be incorporated into the mesh material 52 of the device 50 itself when the mesh material 52 itself is made of a polymer material as mentioned above.
As shown in Figs. 2B, 3B and 4B, the filter device 50 alternatively has 15 anchoring mechanisms 68 such as sharp edges or barbs along the outside periphery of the helix 55, i.e. the turns 65, in order to facilitate securing or anchoring into the vascular wall 12. Additionally, it is also contemplated that the device 50 according to the present invention have any other types of attachment mechanisms suited to the intended environment.
As mentioned above, the deployment mechanism for the filter device 50 may be due to the material 52 itself (when the material 52 is shape-memory material) and will be in the form of a helically wrapped tube (Fig. 6) or a compressed disc (not shown). The delivery device may be a structure solely made up of the compressed filter device 50 itself or alternatively the filter device 50 may be inserted in a delivery mechanism (e.g. a delivery tube or catheter 80 wherein the filter device is loaded in a compressed state between the shaft 82 and cover 85 of the catheter 80).
The mesh material 52 may be of any form, i.e. from a self expanding material such as nitinol to a stainless steel material requiring a delivery mechanism to form it into its final shape, or it may be a polymer or blend of polymers, to name a few examples. The filter device is also made to be retractable (if desired). For instance, due to the nature of the helix design, by applying a twisting action reverse (reverse torque) to that which expanded the filter device when originally deployed in the vessel 10, the filter device 50 can be collapsed and retracted and withdrawn from the vessel 10 and the patient's body. The material 52 can also be of the type that requires a delivery mechanism to form filter device 50 into its final helical shape.
Inasmuch as the foregoing specification comprises preferred embodiments of the invention, it is understood that variations and modifications may be made herein, in accordance with the inventive principles disclosed, without departing from the scope of the invention.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will now occur to those skilled in the art without departing from the 2 o invention. Accordingly, it is intended that the invention be limited only by the spirit and scope of the appended claims.
Patients are likely to remain in the hospital until the supervising physician confirms that the filter is properly fixed in the versa cava and that there are no complications from the procedure. The presence of a versa cava filter does not affect daily routines or the use of other medications. Some patients may remain on anticoagulant drug therapy to reduce the risk of post-insertion clot formation, or risk enlarging a pre-existing clot.
However, there are known complications that may arise in any vena cava filter placement even though known vena cava filters are about 98 percent successful in preventing symptomatic pulmonary embolism. These known filter devices and their placement procedures can be associated with surgical and anesthesia complications to include: bleeding at the insertion site; anesthesia-associated complications such as an allergic reaction or breathing problems; stroke;
pulmonary embolism; and clots. And, as is well known in the field, these complications are not only serious to the patient's health, but they can also be fatal.
z o Thrombosis of the inferior vena cava (IVC) filter after filter placement is frequently reported and may occur with all types of filter presently used in the field.
The occurrence of thrombosis can be delayed from hours to several months after the filter placement, but seems more frequent during the first 3 months. Continued anticoagulation therapy has not been shown to prevent IVC thrombosis.
15 Studies have also shown adverse flow dynamics, such as increased pressure gradients, in the filters with high clot-trapping capacity. Accordingly a device that has a high clot capture efficiency while minimizing the potential for increased pressure gradient is desirable.
Accordingly, what is needed is a device and method that can further reduce 2 o these serious and fatal complications in a more reliable and predictable manner. To date, there have been no known filter devices that are designed in such a manner that can eliminate these complications on a consistent basis, particularly providing for the elimination of complications that may be attributed to pulmonary embolism and blood clots.
The present invention is a novel filter device and method for filtering blood in a vessel that is more highly effective in capturing clots and preventing pulmonary embolism over the known prior art devices and techniques.
SUMMARY OF THE INVENTION
The present invention is a novel filter device and novel method for filtering fluid or blood in a vessel or organ that is more highly effective in capturing clots, emboli, particulate matter and particles and preventing pulmonary embolism over the known prior art devices and techniques The device will also avoid plugging up and restricting blood flow.
The present invention is directed to various embodiments of devices and 1 o methods for trapping or capturing emboli in a vessel of patient's body or organ.
In one embodiment, the present invention is a device for capturing an embolus within a vessel of a patient's body, the device comprising:
at least one helix made of a mesh material, the at least one helix i 5 having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size > 120 ~.m.
2 o In another embodiment, the present invention is a device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the 25 expanded state, the mesh panels having a plurality of pores therein, the pores having a size >_ 120 Nxn.
In another embodiment, the present invention is a device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size > 120 dun.
Another embodiment for the present invention is directed to a method for capturing an embolus within a vessel of a patient's body, the method comprising the 1 o steps of providing a device comprising at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the z5 pores having a size > 120 pm; and placing the device within the vessel of the patient's body.
The method according to the present invention further includes the step of 2 o placing the device within the vessel of the patient's body by moving the device from a collapsed state to an expanded state when placed within a vessel. Other steps include anchoring the device to an inner wall of the vessel, for instance, through using a plurality of barbs.
25 Another embodiment for the present invention is directed toward a method for capturing an embolus within a vessel of a patient's body, the method comprising the steps of:
providing a device comprising at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size > 120 pm, the pores varying in size from a larger size at one end of the at least one helix to a smaller size at an opposite end of the at least one helix; and placing the device within the vessel of the patient's body.
Another method of the present invention is a method for trapping an embolus 1 o within a vessel of a patient's body, the method comprising the steps of providing a device comprising a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the expanded state, the mesh panels having a 1 s plurality of pores therein, the pores having a size > 120 lun; and placing the device within the vessel of the patient's body.
The method further includes the step of placing the device within the vessel of the patient's body by moving the mesh panels of the device from a collapsed state 2 o to an expanded state when placed within a vessel and anchoring the device to an inner wall of the vessel by using an anchoring mechanism or plurality of anchoring mechanisms such as a plurality of barbs.
Another method for the present invention is a method for trapping an 2s embolus within a vessel of a patient's body, the method comprising the steps of:
providing a device comprising a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size 120 pm; and placing the device within the vessel of the patient's body.
In all embodiments of the present invention, pore sizes can vary. For instance all pore sizes can be a size >_ 120 ~m.Moreover, in all embodiments of the present invention, the pore sizes of the device can vary from one end of the device to an opposite end of the device.
1 o For example, the pore size can vary from a larger size pore at one end of the device to a smaller size pore at an opposite end of the device wherein the pore size decreases throughout the entire length of the device, i.e. pore size decreases from the one end to the opposite end of the device such as found with depth type filter devices. The at least 15 one helix having a plurality of turns helically arranged around a longitudinal axis can vary in pitch. This pitch may decrease to zero, to the point where the helix ends by making a full revolution and contacts itself. Additionally, in all embodiments of the present invention, the pore size can be a uniform size throughout the device, 2 o i.e. from one end of the device to the opposite end of the device.
BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with particularity in the appended claims. The invention itself, however, both as to organization and methods of operation, together with further objects and advantages thereof, may be understood by reference to the following description, taken in conjunction with the accompanying drawings in which:
Fig. lA is a schematic illustration of a vessel in cross-section having a helical filter device for capturing emboli in accordance with the present invention;
Fig. I B is an enlarged illustration of a portion of the vessel and filter device of Fig. 1 capturing emboli therein in accordance with the present invention;
s o Fig. 2A is a schematic illustration of another embodiment of the filter device of Figs. 1 A and 1 B in accordance with the present invention;
Fig. 2B is a schematic illustration of the filter device of Fig. 2A haviag a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Fig. 3A is a schematic illustration of another embodiment of the filter device of Figs, lA and 1B having varying pore sizes extending from one end of the device to an opposite end thereof and also including an optional spine in accordance with z 0 the present invention;
Fig. 3B is a schematic illustration of the filter device of Fig. 3A having a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Fig. 4A is a schematic illustration of another embodiment of the filter device of Figs. lA and 1B having a double helix design in accordance with the present invention;
s Fig. 4B is a schematic illustration of the filter device of Fig. 4A having a plurality of anchoring mechanisms for securing the device to the inner wall of a vessel or organ in accordance with the present invention;
Figs. SA, SB and SC are schematic illustrations of a manufacturing method and method for expanding the filter device of Figs lA and 1B in accordance with the present invention; and 1 o Fig. 6 is a schematic illustration of the filter device and device for delivering the f lter device in accordance with the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is a filter device, generally designated 50, having a helical design that is either surface type filter (Figs lA, 1B, 2A, 2B, 4A and 4B) or depth type filter (Figs 3A and 3B) that may be employed in any generally cylindrical pathway such as a vessel IO (Figs. lA and 1B) such as a vein or artery, for example the versa cava, or a duct or an organ of the human body. The filter device 50 and method for using the device 50 is particularly useful for filtering a versa cava and more particularly useful for treatment of vascular disease such as DVT
although the z o device 50 and method of using same is not in any way limited to this particular anatomy or disease state.
The filter device 50 has a helix 55 (as either a single helix or double helix as better described later on below) that is particularly useful for trapping and capturing clots, emboli, particulate matter, particles and thrombus that are migrating or s 5 circulating throughout the circulatory system of the patient or are in danger of breaking apart from attached tissue or structure within the body and migrating or circulating throughout the circulatory system of the patient. As defined herein, the term "clot", "clots", "embolus", "embolism", "emboli", "particulate", "particulate matter", "matter", "particles", "filtrate"; "thrombus", and "thrombi" have the same 2 o meaning for purposes of this disclosure and are used interchangeably throughout and are generally designated as reference numeral 20.
The helix 55 of filter device 50 is made of a mesh material 52 having a plurality of pores 53 throughout the mesh 52. For example, the mesh 52 consists of a 2 s plurality of interlocking strands or fibers or an array of pores 53 made and arranged in the material 52 itself such as through cutting, etching, stamping or the like.
Details for the pores 53 are addressed below.
to The material 52 is any form of material. In one embodiment, the material 52 is a self expanding material such as shape-memory material which can be a metal alloy such as nickel titanium alloy (nitinol). In another embodiment, the material 52 is a stainless steel alloy.. Alternatively, the mesh material 52 is a polymer material. The polymer can be biodegradable and/or bioabsorbable. As used herein, the term "biodegradable" is defined as the breaking down or the susceptibility of a material or component to break down or be broken into products, byproducts, components or subcomponents over time such as days, weeks, months or years. As used herein, the term "bioabsorbable" is defined as the biologic elimination of any of the products of 1 o degradation by metabolism and/or excretion.
The expanded shape of the filter SO comprises at least one helix 55, for example a single helix (Figs lA, 1B, 2A, 2B, 3A and 3B) or a double helix (Figs. 4A
and 4B). The single helix 55 and double helix 55 respectively in some embodiments 1s of the invention comprise a plurality of pleats or panels 60 helically arranged around a longitudinal axis of the device 50. The panels 60 are helically arranged around the longitudinal axis in a plurality of helical turns 65. The helical turns 65 define an inner diameter (ID) and an outer diameter (OD) respectively. Alternatively, the helix 55 of the device 50 is constructed of a single piece of mesh material 52 or discrete 2 o sections of mesh 52 fused or connected to each other forming the single helix or double helix (Figs 4A and 4B) of the filter device 50. The helical turns 65 of filter device have uniform pitch, or alternatively have a variable pitch depending on the channeling effect desired by the end user.
25 It is preferable that the mesh 52 of each turn 65 is sloped, slanted, inclined or curved away from ID of helix 55 to OD of helix 55 such as depicted in the Figs., or alternatively, the helix 55 may have no incline or inclined toward the longitudinal axis. Since the mesh 52 is slanted or curved outwardly from ID to OD for each turn 65 of helix 55, fluid medium is forced and channeled toward the outer circumferential periphery of the helix 55. The panels 60 design for the helix 55 in the embodiments depicted in Figs. 1A and 1B facilitate this outward inclined feature and outward fluid channeling effect.
The helix 55 has a plurality of turns 65 helically arranged around a longitudinal axis that can vary in pitch. This pitch may decrease to zero, to the point where the helix 55 ends or terminates by making a full revolution and contacts itself.
to In some embodiments according to the present invention, the helix 55 includes a spine 57 as best illustrated in Figs 3A and 3B. The spine 57 serves as a central longitudinal shaft or axis for the helical turns 65 of the helix S5.
The spine 57 is optional for the helix 55 since the helix 55 can be constructed without this feature.
15 The filter device 50 is expandable from a compressed, closed, pre-deployed or collapsed state to an open, deployed or expanded state such as partially depicted in Figs SB and SC. For those embodiments having a plurality of panels 60 such as depicted in Figs. lA and 1B, the panels 60 of mesh 52 circumferentially expand upon deployment of the device 50 as best shown by direction arrows in Fig. 5B.
The 2 o filter device 50 is introduced into a lumen 15 of the vessel 10 in the compressed, closed, pre-deployed or collapsed state and the device SO is deployed in the lumen 15 of the vessel 10 by movable expansion of the helix 55 to the open, deployed or expanded state. When moved to the open, deployed or expanded state, the ID of the helix 55 roughly aligns along the longitudinal axis of the vessel 10 and the OD of 25 the helix 55 is adjacent inner wall 12 of the vessel 10.
Additionally, when moved to the open, deployed or expanded state, the helix 55 embeds itself in the wall I2 of the vessel 10 such as shown in Figs lA and 1B. As best illustrated in Figs. 2B, 3B, and 4B, anchoring mechanisms 68, such as a plurality of barbs 68, are used to secure the helix 55 in tissue such as the wall 12 of vessel 10.
The size for each pore 53 is > 120mm. Additionally, in all embodiments of the present invention, the pore size can be a uniform size throughout the entire length of the device 50, i.e. from one end of the device SO to the opposite end of the device 50.
1 o The filter device SO according to the present invention (all embodiments) provides the ability to expose a greater surface area of the filter device 50 due to the unique helix 55 feature. Based on its helical design, the filter device 50 permits a smaller pore structure 53 (over the known filters and filtering methods) because the possibility of stopping venous flow is eliminated. Accordingly, smaller sized clots 15 20, for instance clots 20 having a size >_ 120 p.tn, can be targeted and captured, thereby reducing risk to the patient, i.e, the risk of these smaller size clots 20 causing harm.
Moreover, in all embodiments of the present invention, the pore sizes of the 2 o filter device 50 can vary from one end of the device 50 to an opposite end of the device 50. For example, as best illustrated in Figs 3A and 3B, the pore size can vary from a larger size pore at one end of the device (for example a Smm pore size) to a smaller size pore 53 at an opposite end of the device 50 (for example a 120 wn pore size) such that the pore size decreases throughout the entire length of the device 50, 25 i.e. pore size decreases from the one end to the opposite end of the device 50 thereby increasing the useful life of the device 50 such as found with depth type filter devices. The larger clots 20 are captured at the beginning of the helix 55 of filter device 50 reserving the smaller pore structure portion at opposite or far end of the helix 55 of filter device 50 to remove the smaller clots 20.
The structure of the helix 55 is an expanded mesh 52 that creates the surface filter effect. Any particulate or clot 20 that approaches the filter device 50 according to the present invention encounters what appears to be a solid cylindrical impediment in the lumen 15 of vessel 10 (since OD of helix 55 circumferentially is expanded to and circumferentially conforms to inner wall 12 of vessel 10 as best shown in Figs lA and 1B). However the helical twist of helix 55 allows lower 1 o viscosity fluid medium (such as blood) to flow through pores 53 and around the mesh 52. Any particulate or clot 20 present in this fluid flow will impinge the mesh 52 of the helix 55 and either be trapped there, or be forced out toward the outer periphery of the helix 55 by a helical centrifugal flow effect. The helical structure of the filter device 50 according the present invention also induces outward force by z 5 the outward curvature or inclination of the mesh 52 where the particulate or clot 20 will be trapped. The fluid (blood) is free to move around and passed the clot 20, even if the filter structure is fully covered by particulate or clots 20.
There are several advantages to the helical filter design of the filter device 2 o according to the present invention, for example, the ability of the helix 55 of filter device 50 to filter large amounts of filtrate (clots 20) and completely avoid clogging or plugging the lumen 15 of vessel 10, i.e. vena cava 10 in this example. This is especially important since prior art filters increase the resistance in the lumen 15 of vessel 10 as they are eventually clogged or plugged by particulate matter (clots 20), 25 eventually restricting the flow within vessel 10 thereby cutting off or occluding fluid flow altogether.
The helical filter design of filter device 50 of the present invention captures the filtrate 20 by inertial impaction, or diverts it to the outside edges or periphery of the helix 55 thereby trapping it, while allowing the fluid medium (liquid or gas) to pass around the new obstruction created by the captured filtrate 20.
Other advantages of the filter device 50 of the present invention include the ability to generate a filter having different pore sizes from beginning to end as depicted in Figs. 3A and 3B, mimicking a depth type filter, thereby increasing the filter life. This variable pore size (along the length of the device 50) feature ensures 1 o that larger clots 20 will be captured at the beginning of the filter where the size of pores 53 are larger, reserving the smaller pore structure portion of the filter to remove the smaller clots 20.
Other advantages for the filter device 50 of the present invention relate to its 15 delivery, deliverability and manufacturability. For example, as depicted in Fig. SA, for those embodiments of the present invention made of shape memory material, such as nickel titanium as one example, the shape memory alloy is used as the structure of the filter 50 itself and will also serve as the delivery mechanism for the filter 50 as better described below.
As shown in Fig. SA, the filter device 50 can be laser cut in the general shape of a ribbon out of a tube 40 of shape memory material (nickel titanium in this example). The final cut shape taken from shape memory tube 40 is generally akin to a ribbon as best shown in Fig. 6. The cut device 50 (ribbon-like at this point) is 2 s loaded onto a shaft 82 of a catheter 80 which is akin to taking a ribbon and wrapping it around a pencil. The device 50 is loaded onto shaft 82 by advancing the shaft 82 as cut device 50 is circumferentially wrapped around shaft 82 so that there is no overlap of the device 50 on itself, thereby following a helical pattern. An optional cover 85 is used for the catheter 80 to-keep the wrapped and loaded device 50 compressed in its compressed, closed, pre-deployed or collapsed state.
One geometry, merely used as an example, is depicted in Figs. SA, SB and SC, where the initial shape of device 50 appears to be cut out of a ribbon (Fig. SA), but when expanded, one side/edge expands more than the other generating a circular path (Figs. SB and SC). When the circular path is given an axial component, the helical filter shape (helix 55) of filter device 50 is generated.
1 p Accordingly, as shown in Fig. 6, the filter device 50 according to the present invention provides for an extremely compact delivery method thereby providing flexibility in the delivery method. The helical shape (helix 55, i.e. single helix or double helix design) inherently conforms to the shaft 82 of the catheter 80 and is able to achieve a tight bend radius as shown. Thus, the filter device 50 is self s 5 centering and can easily adapt and function in a tightly constricted and bent environment.
Furthermore, variations for the filter device 50 are also contemplated herein according to the present invention. For example, as mentioned above, the helical 2 o turns 65 of the filter device 50 can have a variable pitch. Additionally, one end of the filter device 50 can coil in on itself, thereby providing an absolute type filter and eliminate any perception that a clot 20 may travel passed the filter 50.
Moreover, the filter device 50 is optionally coated with a drug such as a 25 cytotoxic drug or cytostatic drug in order to make the filter device 50 a drug eluting device for treatment of disease that responds to cytotoxic drugs (for example paclitaxel) or cytostatic drugs (for example one of the rapamycins) respectively. As used herein, the term "drug" or "drugs" are used interchangeably herein and define an agent, drug, compound, composition of matter or mixture thereof which provides some therapeutic, often beneficial, effect such as being cytotoxic or cytostatic as two examples.
This includes pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, antioxidants, plant growth promoters, plant growth inhibitors, preservatives, antipreservatives, disinfectants, sterilization agents, catalysts, chemical reactants, fermentation agents, foods, food supplements, nutrients, cosmetics, drugs, vitamins, sex sterilants, fertility inhibitors, fertility 1 o promoters, microorganism attenuators and other agents that benefit the environment of use. As used herein, the terms fizrther include any physiologically or pharmacologically active substance that produces a localized or systemic effect or effects in animals, including warm blooded mammals, humans and primates;
avians;
domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish;
reptiles; zoo and wild animals; and the like. The active drug that can be delivered includes inorganic and organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, 2 o synoptic sites, neuroeffector functional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants, antiparkinson agents, analgesics, anti-inflammatories, local anesthetics, muscle contractants, blood pressure medications and cholesterol lowering agents including statins, m antimicrobials, antimalarials, hormonal agents including contraceptives, sympathomimetics, polypeptides and proteins capable of eliciting physiological effects, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics, hypoglycemics, nutritional agents and supplements, grourth supplements, fats, ophthalmics, antienteritis agents, electrolytes and diagnostic agents.
Examples of the therapeutic agents or drugs useful in this invention include prochiorperazine edisylate, ferrous sulfate, aminocaproic acid, mecaxylamine 2 o hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride, isoproteronol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate 15 hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperazine maleate, anisindione, diphenadione, erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chlorpropamide, tolazamide, chlormadinone acetate, phenaglycodol, allopur-inol, aluminum aspirin, 2o methotrexate, acetyl sulfisoxazole, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-.beta.-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17-.beta.-hydroxyprogesterone acetate, nor-progesterone, norgestrel, norethindrone, norethisterone, norethiederone, 25 progesterone, norgesterone, norethynodrel, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, is ibuprofen, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, phenoxybenzamine, diltiazem, mili-inone, captropril, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenbufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuninal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinopril, enalapril, captopril, ramipril, enalaprilat, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptylin, and imipramine. Further examples are proteins and peptides which include, but are not s o limited to, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatropin, oxytocin, vasopressin, prolactin, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, 1 s interferons, interleukins, growth hormones such as human growth hormone;
bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors, and human pancreas hormone releasing factor.
2 o Moreover, drugs or pharmaceutical agents useful for the filter device 50 include: antiproliferative/antimitotic agents including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide, teniposide), antibiotics (dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin), anthracyclines, 25 mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (Ir asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents such as G(GP)IIbIIIa inhibitors and vitronectin receptor antagonists;
antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNL~ and analogs, streptozocin), s trazenes - dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine {cladribine}); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, 1 o aminoglutethimide; hormones (i.e, estrogen); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin);
antiinflammatory: such as adrenocortical steroids (cortisol, cortisone, i5 fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal agents (salicylic acid derivatives i.e. aspirin; para-aminophenol derivatives i.e. acetominophen; indole and indene acetic acids (indomethacin, sulindac, and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (ibuprofen and derivatives), 2 o anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives:
(cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); angiogenic agents: vascular endothelial growth factor 2 s (VEGF), fibroblast growth factor (FGF) platelet derived growth factor (PDGF), erythropoetin,; angiotensin receptor blocker; nitric oxide donors; anti-sense oligionucleotides and combinations thereof; cell cycle inhibitors, mTOR
inhibitors, growth factor signal transduction kinase inhibitors, chemical compound, biological molecule, nucleic acids such as DNA and RNA, amino acids, peptide, protein or combinations thereof.
It is to be understood that the use of the term "drug" or drugs" includes all s derivatives, analogs and salts thereof and in no way excludes the use of two or more such drugs.
The one or more drugs are coated on the filter device 50 itself or any desired portion of the device 50, for example, the outer circumferential edge of the helical 1 o turns 65. Moreover, the drug can be used with a polymer coating or the drug can be incorporated into the mesh material 52 of the device 50 itself when the mesh material 52 itself is made of a polymer material as mentioned above.
As shown in Figs. 2B, 3B and 4B, the filter device 50 alternatively has 15 anchoring mechanisms 68 such as sharp edges or barbs along the outside periphery of the helix 55, i.e. the turns 65, in order to facilitate securing or anchoring into the vascular wall 12. Additionally, it is also contemplated that the device 50 according to the present invention have any other types of attachment mechanisms suited to the intended environment.
As mentioned above, the deployment mechanism for the filter device 50 may be due to the material 52 itself (when the material 52 is shape-memory material) and will be in the form of a helically wrapped tube (Fig. 6) or a compressed disc (not shown). The delivery device may be a structure solely made up of the compressed filter device 50 itself or alternatively the filter device 50 may be inserted in a delivery mechanism (e.g. a delivery tube or catheter 80 wherein the filter device is loaded in a compressed state between the shaft 82 and cover 85 of the catheter 80).
The mesh material 52 may be of any form, i.e. from a self expanding material such as nitinol to a stainless steel material requiring a delivery mechanism to form it into its final shape, or it may be a polymer or blend of polymers, to name a few examples. The filter device is also made to be retractable (if desired). For instance, due to the nature of the helix design, by applying a twisting action reverse (reverse torque) to that which expanded the filter device when originally deployed in the vessel 10, the filter device 50 can be collapsed and retracted and withdrawn from the vessel 10 and the patient's body. The material 52 can also be of the type that requires a delivery mechanism to form filter device 50 into its final helical shape.
Inasmuch as the foregoing specification comprises preferred embodiments of the invention, it is understood that variations and modifications may be made herein, in accordance with the inventive principles disclosed, without departing from the scope of the invention.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will now occur to those skilled in the art without departing from the 2 o invention. Accordingly, it is intended that the invention be limited only by the spirit and scope of the appended claims.
Claims (112)
1. A device for capturing an embolus within a vessel of a patient's body, the device comprising:
at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size >=120 µm.
at least one helix made of a mesh material, the at least one helix having a plurality of turns helically arranged around a longitudinal axis, the mesh material having a plurality of pores therein, the pores having a size >=120 µm.
2. The device according to Claim 1, wherein the at least one helix comprises a plurality of panels.
3. The device according to Claim 2, wherein the panels are movable from a collapsed state to an expanded state when placed within a vessel.
4. The device according to Claim 3, wherein the mesh material comprises a self-expanding material.
5. The device according to Claim 4, wherein the self-expanding material comprises a shape memory material.
6. The device according to Claim 5, wherein the shape memory material comprises a metal alloy.
7. The device according to Claim 6, wherein the metal alloy comprises nickel titanium.
8. The device according to Claim 3, wherein the mesh material comprises stainless steel.
9. The device according to Claim 4, wherein the self-expanding material comprises a polymer.
10. The device according to Claim 9, wherein the polymer is biodegradable.
11. The device according to Claim 10, wherein the polymer is bioabsorbable.
12. The device according to Claim 11, further comprising a drug.
13. The device according to Claim 9, further comprising a drug.
14. The device according to Claim 12, wherein the drug is cytostatic.
15. The device according to Claim 14, wherein the drug is a rapamycin.
16. The device according to Claim 12, wherein the drug is cytotoxic.
17. The device according to Claim 16, wherein the drug is paclitaxel.
18. The device according to Claim 13, wherein the drug is cytostatic.
19. The device according to Claim 18, wherein the drug is a rapamycin.
20. The device according to Claim 1, further comprising at least one anchoring mechanism on the at least one helix.
21. The device according to Claim 20, wherein the at least one anchoring mechanism comprises at least one barb.
22. The device according to Claim 1, wherein the at least one helix comprises a double helix.
23. The device according to Claim 22, further comprising at least one anchoring mechanism on the double helix.
24. The device according to Claim 23, wherein the at least one anchoring mechanism comprises at least one barb.
25. The device according to Claim 22, wherein the at least one helix comprises a plurality of panels.
26. The device according to Claim 25, wherein the panels are movable from a collapsed state to an expanded state when placed within a vessel.
27. The device according to Claim 26, wherein the mesh material comprises a self-expanding material.
28. The device according to Claim 27, wherein the self-expanding material comprises a shape memory material.
29. The device according to Claim 28, wherein the shape memory material comprises a metal alloy.
30. The device according to Claim 29, wherein the metal alloy comprises nickel titanium.
31. The device according to Claim 29, wherein the mesh material comprises stainless steel.
32. The device according to Claim 27, wherein the self-expanding material comprises a polymer.
33. The device according to Claim 32, wherein the polymer is biodegradable.
34. The device according to Claim 33, wherein the polymer is bioabsorbable.
35. The device according to Claim 34, further comprising a drug.
36. The device according to Claim 32, further comprising a drug.
37. The device according to Claim 35, wherein the drug is cytostatic.
38. The device according to Claim 37, wherein the drug is a rapamycin.
39. The device according to Claim 35, wherein the drug is cytotoxic.
40. The device according to Claim 39, wherein the drug is paclitaxel.
41. The device according to Claim 36, wherein the drug is cytostatic.
42. The device according to Claim 41, wherein the drug is a rapamycin.
43. The device according to Claim 46, wherein the drug is cytotoxic.
44. The device according to Claim 43, wherein the drug is paclitaxel.
45. The device according to Claim 25, further comprising at least one anchoring mechanism on the at least one helix.
46. The device according to Claim 45, wherein the at least one anchoring mechanism comprises at least one barb.
47. The device according to Claim 1, further comprising a spine.
48. The device according to Claim 22, further comprising a spine.
49. The device according to Claim 1, wherein the pores vary in size from one end of the at least one helix to an opposite end of the at least one helix.
50. The device according to Claim 49, wherein the pores vary in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
51. The device according to Claim 22, wherein the pores vary in size from one end of the double helix to an opposite end of the double helix.
52. The device according to Claim 51, wherein the pores vary in size from a larger size at the one end of the double helix to a smaller size at the opposite end of the double helix.
53. The device according to Claim 49, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
54. The device according to Claim 53, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
55. The device according to Claim 1, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
56. The device according to Claim 55, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
57. A device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size >=120 µm.
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size >=120 µm.
58. The device according to Claim 57, wherein the mesh panels comprise a self-expanding material.
59. The device according to Claim 58, wherein the self-expanding material comprises a shape memory material.
60. The device according to Claim 59, wherein the shape memory material comprises a metal alloy.
61 . The device according to Claim 60, wherein the metal alloy comprises nickel titanium.
62. The device according to Claim 57, wherein the mesh material comprises stainless steel.
63. The device according to Claim 58, wherein the self-expanding material comprises a polymer.
64. The device according to Claim 63, wherein the polymer is biodegradable.
65. The device according to Claim 64, wherein the polymer is bioabsorbable.
66. The device according to Claim 65, further comprising a drug.
67. The device according to Claim 63, further comprising a drug.
68. The device according to Claim 66, wherein the drug is cytostatic.
69. The device according to Claim 68, wherein the drug is a rapamycin.
70. The device according to Claim 66, wherein the drug is cytotoxic.
71. The device according to Claim 70, wherein the drug is paclitaxel.
72. The device according to Claim 67, wherein the drug is cytostatic.
73. The device according to Claim 72, wherein the drug is a rapamycin.
74. The device according to Claim 67, wherein the drug is cytotoxic.
75. The device according to Claim 74, wherein the drug is paclitaxel.
76. The device according to Claim 57, further comprising at least one anchoring mechanism on the at least one helix.
77. The device according to Claim 76, wherein the at least one anchoring mechanism comprises at Least one barb.
78. The device according to Claim 57, further comprising a spine.
79. The device according to Claim 57, wherein the pores vary in size from one end of the at least one helix to an opposite end of the at least one helix.
80. The device according to Claim 79, wherein the pores vary in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
81. The device according to Claim 79, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
82. The device according to Claim 81, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
83. The device according to Claim 57, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
84. The device according to Claim 83, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
85. A device for trapping an embolus within a vessel, the device comprising:
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size >=120 l,µn.
a plurality of mesh panels movable from a collapsed state to an expanded state when placed within a vessel, the mesh panels forming a plurality of turns helically arranged around a longitudinal axis in a double helix arrangement when in the expanded state, the mesh panels having a plurality of pores therein, the pores having a size >=120 l,µn.
86. The device according to Claim 85, wherein the mesh panels comprise a self-expanding material.
87. The device according to Claim 86, wherein the self-expanding material comprises a shape memory material.
88. The device according to Claim 87, wherein the shape memory material comprises a metal alloy.
89. The device according to Claim 88, wherein the metal alloy comprises nickel titanium.
90. The device according to Claim 85, wherein the mesh material comprises stainless steel.
91. The device according to Claim 86, wherein the self-expanding material comprises a polymer.
92. The device according to Claim 91, wherein the polymer is biodegradable.
93. The device according to Claim 92, wherein the polymer is bioabsorbable.
94. The device according to Claim 93, further comprising a drug.
95. The device according to Claim 91, further comprising a drug.
96. The device according to Claim 94, wherein the drug is cytostatic.
97. The device according to Claim 96, wherein the drug is a rapamycin.
98. The device according to Claim 94, wherein the drug is cytotoxic.
99. The device according to Claim 98, wherein the drug is paclitaxel.
100. The device according to Claim 95, wherein the drug is cytostatic.
101. The device according to Claim 100, wherein the drug is a rapamycin.
102. The device according to Claim 95, wherein the drug is cytotoxic.
103. The device according to Claim 102, wherein the drug is paclitaxel.
104. The device according to Claim 85, further comprising at least one anchoring mechanism on the double helix arrangement.
105. The device according to Claim 104, wherein the at least one anchoring mechanism comprises at least one barb.
106. The device according to Claim 85, further comprising a spine.
107. The device according to Claim 85, wherein the pores vary in size from one end of the at least one helix to an opposite end of the at least one helix.
108. The device according to Claim 107, wherein the pores vary in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
109. The device according to Claim 107, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
110. The device according to Claim 109, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
111.The device according to Claim 85, wherein the pitch of the at least one helix varies in size from one end of the at least one helix to an opposite end of the at least one helix.
112.The device according to Claim 111, wherein the pitch of the at least one helix varies in size from a larger size at the one end of the at least one helix to a smaller size at the opposite end of the at least one helix.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/896,571 | 2004-07-21 | ||
US10/896,571 US20060020286A1 (en) | 2004-07-22 | 2004-07-22 | Device for filtering blood in a vessel with helical elements |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2512232A1 true CA2512232A1 (en) | 2006-01-21 |
CA2512232C CA2512232C (en) | 2013-12-10 |
Family
ID=35004290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2512232A Expired - Fee Related CA2512232C (en) | 2004-07-21 | 2005-07-12 | Device for filtering blood in a vessel with helical elements |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060020286A1 (en) |
EP (1) | EP1618855B1 (en) |
KR (1) | KR20060046550A (en) |
AU (1) | AU2005202799B2 (en) |
CA (1) | CA2512232C (en) |
HK (1) | HK1086182A1 (en) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6575997B1 (en) * | 1999-12-23 | 2003-06-10 | Endovascular Technologies, Inc. | Embolic basket |
US6402771B1 (en) | 1999-12-23 | 2002-06-11 | Guidant Endovascular Solutions | Snare |
US6660021B1 (en) * | 1999-12-23 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Intravascular device and system |
US6695813B1 (en) | 1999-12-30 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US7918820B2 (en) * | 1999-12-30 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Device for, and method of, blocking emboli in vessels such as blood arteries |
US6540722B1 (en) * | 1999-12-30 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US20040167567A1 (en) * | 2001-03-23 | 2004-08-26 | Cano Gerald G. | Method and apparatus for capturing objects beyond an operative site in medical procedures |
US6939362B2 (en) * | 2001-11-27 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Offset proximal cage for embolic filtering devices |
US6964670B1 (en) * | 2000-07-13 | 2005-11-15 | Advanced Cardiovascular Systems, Inc. | Embolic protection guide wire |
US6537294B1 (en) * | 2000-10-17 | 2003-03-25 | Advanced Cardiovascular Systems, Inc. | Delivery systems for embolic filter devices |
US6893451B2 (en) * | 2000-11-09 | 2005-05-17 | Advanced Cardiovascular Systems, Inc. | Apparatus for capturing objects beyond an operative site utilizing a capture device delivered on a medical guide wire |
US6506203B1 (en) * | 2000-12-19 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Low profile sheathless embolic protection system |
US6645223B2 (en) * | 2001-04-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Deployment and recovery control systems for embolic protection devices |
US6929652B1 (en) * | 2001-06-01 | 2005-08-16 | Advanced Cardiovascular Systems, Inc. | Delivery and recovery systems having steerability and rapid exchange operating modes for embolic protection systems |
US7338510B2 (en) * | 2001-06-29 | 2008-03-04 | Advanced Cardiovascular Systems, Inc. | Variable thickness embolic filtering devices and method of manufacturing the same |
US6599307B1 (en) * | 2001-06-29 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Filter device for embolic protection systems |
US20030032941A1 (en) * | 2001-08-13 | 2003-02-13 | Boyle William J. | Convertible delivery systems for medical devices |
US6638294B1 (en) | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
US6887258B2 (en) * | 2002-06-26 | 2005-05-03 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices for bifurcated vessels |
US7331973B2 (en) * | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
US7252675B2 (en) * | 2002-09-30 | 2007-08-07 | Advanced Cardiovascular, Inc. | Embolic filtering devices |
US20040064099A1 (en) * | 2002-09-30 | 2004-04-01 | Chiu Jessica G. | Intraluminal needle injection substance delivery system with filtering capability |
US20040088000A1 (en) * | 2002-10-31 | 2004-05-06 | Muller Paul F. | Single-wire expandable cages for embolic filtering devices |
FR2847151B1 (en) * | 2002-11-15 | 2005-01-21 | Claude Mialhe | OCCLUSIVE DEVICE WITH MEDICAL OR SURGICAL DESTINATION |
US8591540B2 (en) * | 2003-02-27 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Embolic filtering devices |
US20040172055A1 (en) * | 2003-02-27 | 2004-09-02 | Huter Scott J. | Embolic filtering devices |
US7892251B1 (en) | 2003-11-12 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Component for delivering and locking a medical device to a guide wire |
US20110236699A1 (en) * | 2003-11-14 | 2011-09-29 | Tundra Composites, LLC | Work piece comprising metal polymer composite with metal insert |
US7678129B1 (en) | 2004-03-19 | 2010-03-16 | Advanced Cardiovascular Systems, Inc. | Locking component for an embolic filter assembly |
WO2005094283A2 (en) | 2004-03-25 | 2005-10-13 | Hauser David L | Vascular filter device |
EP1788956B1 (en) * | 2004-09-17 | 2011-11-09 | Codman & Shurtleff, Inc. | Vascular occlusion device with an embolic mesh ribbon |
US20080147111A1 (en) * | 2005-01-03 | 2008-06-19 | Eric Johnson | Endoluminal Filter With Fixation |
US20060241677A1 (en) * | 2005-01-03 | 2006-10-26 | Eric Johnson | Methods for maintaining a filtering device within a lumen |
US20060184194A1 (en) * | 2005-02-15 | 2006-08-17 | Cook Incorporated | Embolic protection device |
US9259305B2 (en) | 2005-03-31 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Guide wire locking mechanism for rapid exchange and other catheter systems |
US20070088382A1 (en) * | 2005-10-13 | 2007-04-19 | Bei Nianjiong J | Embolic protection recovery catheter assembly |
US20070112371A1 (en) * | 2005-11-14 | 2007-05-17 | Medtronic Vascular, Inc. | Embolic protection filter having compact collapsed dimensions and method of making same |
US20070112372A1 (en) * | 2005-11-17 | 2007-05-17 | Stephen Sosnowski | Biodegradable vascular filter |
US20070282418A1 (en) * | 2006-05-30 | 2007-12-06 | Boston Scientific Scimed, Inc. | Anti-obesity flow controller |
US20080215072A1 (en) * | 2007-02-15 | 2008-09-04 | Graham Kelly | Methods and apparatus for utilization of barbed sutures in human tissue including a method for eliminating or improving blood flow in veins |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
US7867273B2 (en) | 2007-06-27 | 2011-01-11 | Abbott Laboratories | Endoprostheses for peripheral arteries and other body vessels |
US9034007B2 (en) * | 2007-09-21 | 2015-05-19 | Insera Therapeutics, Inc. | Distal embolic protection devices with a variable thickness microguidewire and methods for their use |
WO2009053855A2 (en) * | 2007-10-27 | 2009-04-30 | Salviac Limited | Embolic filter device and method of manufacturing the same |
US9402707B2 (en) | 2008-07-22 | 2016-08-02 | Neuravi Limited | Clot capture systems and associated methods |
US20100274231A1 (en) * | 2009-04-24 | 2010-10-28 | Applied Medical Resources Corporation | Renal flushing catheter |
EP2539012B1 (en) | 2010-02-23 | 2018-01-24 | Covidien LP | Devices for vascular recanalization |
EP2629684B1 (en) | 2010-10-22 | 2018-07-25 | Neuravi Limited | Clot engagement and removal system |
US11259824B2 (en) | 2011-03-09 | 2022-03-01 | Neuravi Limited | Clot retrieval device for removing occlusive clot from a blood vessel |
US9301769B2 (en) | 2011-03-09 | 2016-04-05 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US10426501B2 (en) | 2012-01-13 | 2019-10-01 | Crux Biomedical, Inc. | Retrieval snare device and method |
US10548706B2 (en) | 2012-01-13 | 2020-02-04 | Volcano Corporation | Retrieval snare device and method |
US10213288B2 (en) | 2012-03-06 | 2019-02-26 | Crux Biomedical, Inc. | Distal protection filter |
US20130338690A1 (en) * | 2012-06-15 | 2013-12-19 | Gadal Consulting, LLC | Device and method for removing unwanted material in a vascular conduit |
US20150238207A1 (en) | 2012-09-24 | 2015-08-27 | Inceptus Medical LLC | Device and method for treating vascular occlusion |
US8784434B2 (en) | 2012-11-20 | 2014-07-22 | Inceptus Medical, Inc. | Methods and apparatus for treating embolism |
CA2896028C (en) * | 2012-12-20 | 2021-03-09 | Promedica Health System, Inc. | Biodegradable intravascular filter |
US9119948B2 (en) | 2013-02-20 | 2015-09-01 | Covidien Lp | Occlusive implants for hollow anatomical structures, delivery systems, and related methods |
US9433429B2 (en) | 2013-03-14 | 2016-09-06 | Neuravi Limited | Clot retrieval devices |
WO2014140092A2 (en) | 2013-03-14 | 2014-09-18 | Neuravi Limited | Devices and methods for removal of acute blockages from blood vessels |
ES2960917T3 (en) | 2013-03-14 | 2024-03-07 | Neuravi Ltd | Clot retrieval device to remove occlusive clots from a blood vessel |
US8715314B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment measurement methods |
US8679150B1 (en) | 2013-03-15 | 2014-03-25 | Insera Therapeutics, Inc. | Shape-set textile structure based mechanical thrombectomy methods |
SG10201709513PA (en) | 2013-03-15 | 2018-01-30 | Insera Therapeutics Inc | Vascular treatment devices and methods |
US8690907B1 (en) | 2013-03-15 | 2014-04-08 | Insera Therapeutics, Inc. | Vascular treatment methods |
GB2523291B (en) * | 2013-10-16 | 2016-02-24 | Cook Medical Technologies Llc | Vascular occluder with crossing frame elements |
WO2015061365A1 (en) | 2013-10-21 | 2015-04-30 | Inceptus Medical, Llc | Methods and apparatus for treating embolism |
US10350098B2 (en) | 2013-12-20 | 2019-07-16 | Volcano Corporation | Devices and methods for controlled endoluminal filter deployment |
WO2015191646A1 (en) | 2014-06-09 | 2015-12-17 | Inceptus Medical, Llc | Retraction and aspiration device for treating embolism and associated systems and methods |
US11253278B2 (en) | 2014-11-26 | 2022-02-22 | Neuravi Limited | Clot retrieval system for removing occlusive clot from a blood vessel |
US10617435B2 (en) | 2014-11-26 | 2020-04-14 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
EP3223723B1 (en) * | 2014-11-26 | 2020-01-08 | Neuravi Limited | A clot retrieval device for removing occlusive clot from a blood vessel |
US9700332B2 (en) | 2015-10-23 | 2017-07-11 | Inari Medical, Inc. | Intravascular treatment of vascular occlusion and associated devices, systems, and methods |
EP3364891B1 (en) | 2015-10-23 | 2023-08-09 | Inari Medical, Inc. | Device for intravascular treatment of vascular occlusion |
US10342571B2 (en) | 2015-10-23 | 2019-07-09 | Inari Medical, Inc. | Intravascular treatment of vascular occlusion and associated devices, systems, and methods |
CN108601599B (en) * | 2015-11-25 | 2021-08-13 | 尼尔拉维有限公司 | Clot retrieval device for removing an occluded clot from a blood vessel |
DE102015120554A1 (en) * | 2015-11-26 | 2017-06-01 | Phenox Gmbh | Belt-shaped occlusion device |
JP2019508201A (en) | 2016-02-16 | 2019-03-28 | インセラ セラピューティクス,インク. | Suction device and fixed blood flow bypass device |
MX2019002565A (en) | 2016-09-06 | 2019-09-18 | Neuravi Ltd | A clot retrieval device for removing occlusive clot from a blood vessel. |
EP3528717A4 (en) | 2016-10-24 | 2020-09-02 | Inari Medical, Inc. | Devices and methods for treating vascular occlusion |
CN106390603B (en) * | 2016-12-13 | 2018-07-10 | 宜兴市力克环保设备有限公司 | DNA double spiral micron order filter core |
WO2019050765A1 (en) | 2017-09-06 | 2019-03-14 | Inari Medical, Inc. | Hemostasis valves and methods of use |
US11154314B2 (en) | 2018-01-26 | 2021-10-26 | Inari Medical, Inc. | Single insertion delivery system for treating embolism and associated systems and methods |
US11471582B2 (en) | 2018-07-06 | 2022-10-18 | Incept, Llc | Vacuum transfer tool for extendable catheter |
US11559382B2 (en) | 2018-08-13 | 2023-01-24 | Inari Medical, Inc. | System for treating embolism and associated devices and methods |
US10842498B2 (en) | 2018-09-13 | 2020-11-24 | Neuravi Limited | Systems and methods of restoring perfusion to a vessel |
US11406416B2 (en) | 2018-10-02 | 2022-08-09 | Neuravi Limited | Joint assembly for vasculature obstruction capture device |
US11272945B2 (en) | 2018-10-10 | 2022-03-15 | Innova Vascular, Inc. | Device for removing an embolus |
CA3157521A1 (en) | 2019-10-16 | 2021-04-22 | Inari Medical, Inc. | Systems, devices, and methods for treating vascular occlusions |
US11712231B2 (en) | 2019-10-29 | 2023-08-01 | Neuravi Limited | Proximal locking assembly design for dual stent mechanical thrombectomy device |
US11517340B2 (en) | 2019-12-03 | 2022-12-06 | Neuravi Limited | Stentriever devices for removing an occlusive clot from a vessel and methods thereof |
US11633272B2 (en) | 2019-12-18 | 2023-04-25 | Imperative Care, Inc. | Manually rotatable thrombus engagement tool |
US11871946B2 (en) | 2020-04-17 | 2024-01-16 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US11730501B2 (en) | 2020-04-17 | 2023-08-22 | Neuravi Limited | Floating clot retrieval device for removing clots from a blood vessel |
US11717308B2 (en) | 2020-04-17 | 2023-08-08 | Neuravi Limited | Clot retrieval device for removing heterogeneous clots from a blood vessel |
US11805998B2 (en) | 2020-04-20 | 2023-11-07 | Covidien Lp | Devices and methods for obtaining adenomyosis and other biopsy samples |
US11737771B2 (en) | 2020-06-18 | 2023-08-29 | Neuravi Limited | Dual channel thrombectomy device |
US11937836B2 (en) | 2020-06-22 | 2024-03-26 | Neuravi Limited | Clot retrieval system with expandable clot engaging framework |
US11395669B2 (en) | 2020-06-23 | 2022-07-26 | Neuravi Limited | Clot retrieval device with flexible collapsible frame |
US11439418B2 (en) | 2020-06-23 | 2022-09-13 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US11864781B2 (en) | 2020-09-23 | 2024-01-09 | Neuravi Limited | Rotating frame thrombectomy device |
US11937837B2 (en) | 2020-12-29 | 2024-03-26 | Neuravi Limited | Fibrin rich / soft clot mechanical thrombectomy device |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1204643A (en) * | 1981-09-16 | 1986-05-20 | Hans I. Wallsten | Device for application in blood vessels or other difficulty accessible locations and its use |
US4643184A (en) * | 1982-09-29 | 1987-02-17 | Mobin Uddin Kazi | Embolus trap |
SE450809B (en) * | 1985-04-10 | 1987-08-03 | Medinvent Sa | PLANT TOPIC PROVIDED FOR MANUFACTURING A SPIRAL SPRING SUITABLE FOR TRANSLUMINAL IMPLANTATION AND MANUFACTURED SPIRAL SPRINGS |
US6171338B1 (en) * | 1988-11-10 | 2001-01-09 | Biocon, Oy | Biodegradable surgical implants and devices |
US5160342A (en) * | 1990-08-16 | 1992-11-03 | Evi Corp. | Endovascular filter and method for use thereof |
US5129910A (en) * | 1991-07-26 | 1992-07-14 | The Regents Of The University Of California | Stone expulsion stent |
US5192286A (en) * | 1991-07-26 | 1993-03-09 | Regents Of The University Of California | Method and device for retrieving materials from body lumens |
US5879366A (en) * | 1996-12-20 | 1999-03-09 | W.L. Gore & Associates, Inc. | Self-expanding defect closure device and method of making and using |
US5911734A (en) * | 1997-05-08 | 1999-06-15 | Embol-X, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US6361545B1 (en) * | 1997-09-26 | 2002-03-26 | Cardeon Corporation | Perfusion filter catheter |
US6063111A (en) * | 1998-03-31 | 2000-05-16 | Cordis Corporation | Stent aneurysm treatment system and method |
US6840950B2 (en) * | 2001-02-20 | 2005-01-11 | Scimed Life Systems, Inc. | Low profile emboli capture device |
US7270668B2 (en) * | 2001-12-03 | 2007-09-18 | Xtent, Inc. | Apparatus and methods for delivering coiled prostheses |
US8114114B2 (en) * | 2002-08-27 | 2012-02-14 | Emboline, Inc. | Embolic protection device |
US7846198B2 (en) * | 2002-12-24 | 2010-12-07 | Novostent Corporation | Vascular prosthesis and methods of use |
US20050228417A1 (en) * | 2004-03-26 | 2005-10-13 | Teitelbaum George P | Devices and methods for removing a matter from a body cavity of a patient |
-
2004
- 2004-07-22 US US10/896,571 patent/US20060020286A1/en not_active Abandoned
-
2005
- 2005-06-27 AU AU2005202799A patent/AU2005202799B2/en not_active Ceased
- 2005-07-12 CA CA2512232A patent/CA2512232C/en not_active Expired - Fee Related
- 2005-07-21 KR KR1020050066412A patent/KR20060046550A/en not_active Application Discontinuation
- 2005-07-21 EP EP05254564.7A patent/EP1618855B1/en not_active Not-in-force
-
2006
- 2006-06-01 HK HK06106334.6A patent/HK1086182A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20060046550A (en) | 2006-05-17 |
AU2005202799A1 (en) | 2006-02-09 |
AU2005202799B2 (en) | 2011-09-08 |
EP1618855A1 (en) | 2006-01-25 |
US20060020286A1 (en) | 2006-01-26 |
HK1086182A1 (en) | 2006-09-15 |
EP1618855B1 (en) | 2015-12-09 |
CA2512232C (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2512232C (en) | Device for filtering blood in a vessel with helical elements | |
AU2005203022B2 (en) | Method for filtering blood in a vessel with helical elements | |
EP1600178B1 (en) | Biodegradable vascular device with buffering agent | |
US7803182B2 (en) | Biodegradable vascular device with buffering agent | |
US20230173225A1 (en) | Indwelling luminal devices | |
CN106344233B (en) | Casing for expansible medical device | |
EP2882372B1 (en) | Dual net vascular filtration devices | |
JP4739223B2 (en) | Implantable valve prosthesis | |
EP1676546B1 (en) | Distal protection apparatus with improved wall apposition | |
JP4510025B2 (en) | Implantable valve prosthesis | |
EP3808400B1 (en) | Deconstructable endoluminal devices and related systems and methods | |
EP1676545A1 (en) | Distal protection device with improved wall apposition | |
EP1997459A1 (en) | Stent/fibre structural combinations | |
JP2013059643A (en) | Graft and stent graft having radiopaque beading | |
IL169696A (en) | Device for filtering blood in a vessel with helical elements | |
EP3076879B1 (en) | Anastomotic connector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220712 |